EVO756 + EVO756 + EVO756 + Placebo control
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atoptic Dermatitis
Conditions
Atoptic Dermatitis
Trial Timeline
Aug 26, 2025 → Jul 1, 2026
NCT ID
NCT07150845About EVO756 + EVO756 + EVO756 + Placebo control
EVO756 + EVO756 + EVO756 + Placebo control is a phase 2 stage product being developed by Evommune for Atoptic Dermatitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07150845. Target conditions include Atoptic Dermatitis.
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07150845 | Phase 2 | Recruiting |
| NCT06873516 | Phase 2 | Recruiting |